Bayer wakes up ECM with promise of huge rights issue
A lacklustre year for equity capital markets suddenly grew more interesting on Monday, when Bayer announced the details of a $62bn bid for Monsanto. It got still more interesting on Tuesday, when the US agribusiness group rejected the offer as “incomplete and financially inadequate”.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: